Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

By Jonathan Gardner • April 28, 2026

Sanofi MS drug rejected in US gets an endorsement in Europe

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval. 

By Delilah Alvarado • April 24, 2026

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

By Jonathan Gardner • April 23, 2026

Sanofi posts upbeat sales as R&D pressure builds

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.

By Kristin Jensen • April 23, 2026

An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?

A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”

By Alexandra Pecci • April 22, 2026

Merck’s fast-ascending kidney cancer drug hits a setback

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

By Ben Fidler • April 21, 2026

What actually drives speed in complex drug development programs

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

By Doug Ahrens, Program Transformation Director, Integrated Supply & Delivery, Thermo Fisher Scientific • April 20, 2026

5 notable pharma CEO pay hikes in 2025

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”

By Alexandra Pecci • April 17, 2026

Lilly’s new obesity pill passes heart safety test in diabetes

The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes.

By Jonathan Gardner • April 16, 2026

FDA asks Lilly to evaluate obesity pill’s liver risk

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.

By Jonathan Gardner • April 15, 2026

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.

By Jonathan Gardner • April 14, 2026

Connected medical devices: Smarter care starts here

Connected medical devices are transforming healthcare and clinical trials, driving advances in patient care and next-gen therapies shaping the future.

April 13, 2026

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

By Kristin Jensen • April 9, 2026

With 3 quick buyouts, Gilead leans into its latest transformation

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it’s long struggled to execute.

By Jonathan Gardner • April 8, 2026

Sanofi immune drug hopeful posts mixed results in mid-stage tests

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

By Ben Fidler • April 7, 2026

Under-the-skin Tepezza comparable to infused version in key study, Amgen says

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing. 

By Delilah Alvarado • April 6, 2026

Trump revives pharma tariffs with 100% charges, but leaves loopholes

"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should be low," according to one analyst.

By Jonathan Gardner • April 3, 2026

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.

By BioPharma Dive staff • April 2, 2026

Pfizer, BioNTech to pause COVID vaccine study due to low enrollment

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

By Delilah Alvarado • April 1, 2026

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.

By Jonathan Gardner • April 1, 2026

FDA, after turbulent year, leaves drugmakers guessing on its direction

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it’s ever been.

By Jonathan Gardner , Shaun Lucas • April 1, 2026

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.

By Jonathan Gardner • March 31, 2026

Lilly’s AI commitment expands through deal with Insilico

A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks to sustain its industry lead.

By Jonathan Gardner • March 30, 2026

Otsuka picks up PTSD drug with $700M Transcend buy

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly “paradigm-shifting therapy” in psychiatry.

By Jacob Bell • March 27, 2026

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. 

By Jonathan Gardner • March 27, 2026